Maribavir treatment for refractory and drug-intolerant cytomegalovirus viremia and disease after allogeneic hematopoietic stem cell transplantation: a clinical analysis of 25 cases
10.3760/cma.j.cn121090-20240919-00355
- VernacularTitle:马立巴韦治疗异基因造血干细胞移植后难治与药物不耐受CMV血症和CMV病25例临床分析
- Author:
Wei MA
1
;
Zhijie WEI
;
Yue LU
;
Jianping ZHANG
;
Ruijuan SUN
;
Min XIONG
;
Jiarui ZHOU
;
Lei DONG
;
Song XUE
;
Xingyu CAO
Author Information
1. 河北燕达陆道培医院造血干细胞移植科，廊坊 065201
- Publication Type:Journal Article
- Keywords:
Cytomegalovirus;
Allogeneic hematopoietic stem cell transplantation;
Maribavir
- From:
Chinese Journal of Hematology
2024;45(11):1010-1015
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the safety and efficacy of maribavir for the treatment of CMV viremia and CMV disease refractory or intolerant to conventional antiviral drugs after allogeneic hematopoietic stem cell transplantation (allo-HSCT) .Methods:This study retrospectively analyzed the clinical characteristics and outcomes of CMV viremia and CMV disease refractory or intolerant to conventional antiviral drugs after allo-HSCT treated with maribavir at Hebei Yanda Lu Daopei Hospital from April 2024 to September 2024.Result:A total of 25 patients received maribavir, including 21 haploidentical transplants, two sibling HLA-matched transplants, and 2 HLA-matched unrelated transplants. Among them, 21, 2, and 2 patients received the first, second, and third transplants, respectively. The median time to the onset of CMV viremia and CMV disease was 120.5 (6-298) days post-transplantation. The median peak plasma CMV copy number was 6 400 copies/ml (range: 1 100-650 000 copies/ml). Six patients were diagnosed with CMV disease. Maribavir was administered after a median of 9.5 (1-41) days after CMV infection. The median duration of maribavir administration was 11.5 (6-43) days. Post-treatment, maribavir was effective in 25 (100%) patients. Two patients experienced grade 1 taste abnormalities, and one patient experienced grade 2 myelosuppression.Conclusion:The application of maribavir after allo-HSCT for treating refractory, drug-intolerant CMV viremia and CMV disease is safe and effective.
